TrialSignal
Clinical trial intelligence report
Aspirin Supplementation for Pregnancy Indicated Risk Reduction in Nulliparas (ASPIRIN): Neurodevelopmental Follow-up Trial
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04888377
Status
COMPLETED
Phase
Completed
Sponsor
NICHD Global Network for Women's and Children's Health
Executive brief
Investment-Ready Snapshot
The ASPIRIN Neurodevelopmental Follow-up Trial aimed to assess the impact of antenatal low-dose aspirin on the neurodevelopment of children whose mothers participated in the original ASPIRIN trial. The study enrolled 620 children across multiple sites in low- and middle-income countries, focusing on cognitive, language, and motor development outcomes at 36 months of age.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04888377
Indication
Neurodevelopmental Abnormality
Modality
small molecule
Target
Neurodevelopmental Abnormality
Intervention
Aspirin, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.